Physicians often recommend that transgender women who are undergoing gender-affirming surgery suspend hormone therapy to reduce the risk of venous thromboembolism (VTE). In a study with the potential to change current practice, a Mount Sinai research team found the risk of blood clots to be minimal, and that patients can safely remain on critical estrogen therapy during their surgery. The study was published in March 2021 in The Journal of Clinical Endocrinology and Metabolism.
Referring a patient is easy. Just click the “Refer a Patient Online” button.